TABLE 5

Clinical and inflammatory characteristics of participants with and without a high abundance of Haemophilus sequences (Haemophilus high and Haemophilus low groups)

Haemophilus highHaemophilus lowp-value
Subjects624
Age years45±1462±7<0.001
Male5 (83)7 (29)0.026
Atopic6 (100)18 (78)0.283
Ex-smoker0 (0)16 (67)0.005
Smoking pack-years14.4 (1.9, 40.3)
FEV1 % predicted82.2±14.276.2±17.90.452
FEV1/FVC %73.2±8.8)67.6±10.50.241
ICS dose µg2000 (2000, 2000)2000 (900, 2000)0.393
ACQ6 score1.19±0.681.44±1.000.571
VAS symptom scores
 Breathlessness2.8 (1.1, 8.0)7.0 (4.8, 18.0)0.077
 Wheeze1.1 (0.8, 2.0)4.0 (1.1, 7.0)0.063
 Cough5.0 (3.0, 6.0)7.2 (1.8, 10.0)0.706
 Sputum production2.7 (0.7, 3.3)5.9 (1.8, 10.0)0.215
Inflammatory cell counts
 Neutrophilic asthma4 (67)3 (15)0.024
 Total cell count ×106 mL–17.0 (3.5, 8.4)4.4 (2.5, 8.6)0.568
 Viability %82 (75, 84)82 (76, 90)0.484
 Neutrophils %61.2±33.635.9±19.80.027
 Eosinophils %1.3 (0.3, 4.3)1.6 (0.5, 3.6)0.917
 Macrophages %23.8 (14.8, 42.3)46.3 (34.8, 62.5)0.087
 Lymphocytes %1.5 (0.5, 2.5)0.5 (0.3, 1.0)0.104
 Columnar epithelial cells %0.4 (0.3, 1.0)1.8 (0.4, 3.3)0.152
 Squamous cells %5.6 (1.0, 9.9)3.7 (1.1, 7.0)0.622
  • Data are presented as n, mean±sd, n (%) or median (quartile 1, quartile 3), unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ6: Asthma Control Questionnaire 6; ICS: inhaled corticosteroid; VAS: visual analogue scale.